menu
    • menu

    Company profile for Corbus Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist...
    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Corbus PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    500 River Ridge Drive, Second Floor, Norwood, MA 02062
    Telephone
    Telephone
    617.963.0100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.corbuspharma.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/corbus-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/CorbusPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corbus Pharma Reports Results from Phase 1a Study of CRB-913
    Corbus Pharma Reports Results from Phase 1a Study of CRB-913

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203762/0/en/Corbus-Pharmaceuticals-Reports-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-Demonstrating-Favorable-Safety-Profile-and-Emerging-Evi.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Corbus Pharma To Present Phase 1A Results Of Oral CRB-913
    Corbus Pharma To Present Phase 1A Results Of Oral CRB-913

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203493/0/en/Corbus-Pharmaceuticals-to-Report-Results-from-Phase-1a-Study-of-Oral-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-for-Obesity-on-Thursday-December-11-2025.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Corbus Pharma Updates On Q3 2025 Finances & Corporate Progress
    Corbus Pharma Updates On Q3 2025 Finances & Corporate Progress

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186184/0/en/Corbus-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Corbus Pharma To Join Investor Conferences
    Corbus Pharma To Join Investor Conferences

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3182532/0/en/Corbus-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Corbus Pharmaceuticals Announces Pricing of Public Offering
    Corbus Pharmaceuticals Announces Pricing of Public Offering

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178107/0/en/Corbus-Pharmaceuticals-Announces-Pricing-of-Public-Offering.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Corbus Pharmaceuticals Announces Proposed Public Offering
    Corbus Pharmaceuticals Announces Proposed Public Offering

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177983/0/en/Corbus-Pharmaceuticals-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search